non glp 1 drugs for weight loss with GLP-1 medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans GLP-1 and similar hormone-activating medications

Food and Drug Administration approved the first GLP-1 medications in 2005

A significant reduction in alcohol intake was observed at follow-up compared with baseline, including among adults who were considered high alcohol consumers and drank more than 11 U alcohol per week at the start of the study

As part of our comprehensive approach to medical aesthetics and wellness, we offer advanced weight management solutions, including semaglutide therapy

As extensively described elsewhere [for a review, see Koob (2014)], AUD involves recurring cycles of specific behaviors, involving an initial binge/reward phase followed by compulsive alcohol intake, which transitions into drinking with an aim to reduce the negative effects and the presence of withdrawal symptoms

At present, bariatric surgery (BS) is considered the benchmark treatment of morbid obesity, with well-established indications providing effective long-term outcomes [2, 3] that lead to sustained weight loss [4] and improvement in most weight-related comorbidities [5,6,7], with relatively low morbidity and mortality [8,9,10]

Leehey DJ, Singh AK, Alavi N, Singh R (2000) Role of angiotensin II in diabetic nephropathy